The MIMICS Clinical Programme:

An evolving database of the safety and effectiveness of the BioMimics 3D Vascular Stent System. Gathering clinical evidence from a “real world” patient population from single de novo to complex, long and severely calcified lesions.

MIMICS-RCT

A randomized study comparing safety and effectiveness of the BioMimics 3D Vascular Stent System to a straight control stent. The difference in freedom from loss of primary patency was statistically significant through 2 years, favouring the BioMimics 3D Vascular Stent System (72% vs 55% at two years, log-rank test P=0.05). Between 12 and 24 months, there were no additional cases of CDTLR in patients with the BioMimics-3D Vascular Stent System (91% at1 & 2 years), while the number of cases of CDTLR with the control straight stent increased threefold (log-rank test P=0.03)1. There were no stent fractures at 2 years.2

KM Freedom from CDTLR – 12 Month Landmark Analysis3

*CDTLR determined through event adjudication

MIMICS-2

A multicentre, international (USA, Japan and Germany) IDE study. At 3 years follow-up BioMimics 3D demonstrated continuing benefit with CDTLR showing comparable outcomes to DES/DCB. Core Lab X-ray imaging review confirmed 0% stent fracture in any MIMICS-2 subject treated with BioMimics.
MIMICS-2 represents a more challenging patient population than in DES/DCB pivotal trials.​4,5

Continuing benefit at 3 years even in challenging cases6

MIMICS-3D

A prospective observational registry evaluating the BioMimics 3D Vascular Stent System in a real-world clinical population with a dedicated subgroup analysis of device performance as a complementary treatment in procedures involving drug-coated balloons. MIMICS-3D enrolled 507 patients across 23 clinical sites in Europe.

KM Freedom from CDTLR at 2 years7

MIMICS-3D USA

A prospective, multicentre observational study evaluating the safety, effectiveness, and device performance of the BioMimics 3D Vascular Stent System within a real-world clinical population of patients undergoing femoropopliteal intervention. MIMICS-3D USA will enrol a minimum of 500 patients in up to 40 sites across the United States. Enrolment ongoing

1. Data on file at Veryan Medical treatment in procedures involving drug-coated balloons.
2. Zeller T. et al; Circ Cardiovasc Interv. 2016;9
3. Sullivan TM et al; Int J Vasc Med. 2018
4. Kenneth Rosenfield et al: N Engl J Med 2015;373:145-53. DOI: 10.1056/NEJMoa1406235
5. Michael D. Dake et al: Circ Cardiovasc Interv. 2011;4:495-504
6. Data on file at Veryan Medical – MIMICS 2 Clinical Study Report

7. Data on file at Veryan Medical – MIMICS 3D Clinical Study Report

Discover The BioMimics 3D Vascular Stent System

Ordering information

For customer service and ordering information

Technical information

Technical Information for the BioMimics 3D Vascular Stent System.

BioMimics 3D® Vascular Stent System

The BioMimics 3D Vascular Stent System has a unique 3D helical geometry which imparts a gentle helical shape to the stented artery.